News releases
Find out what's happening
28 April 2022
2022 AGM: Chairman's address
2022 AGM: Chairman's address
21 March 2022
BAT Announces Management Board Change
BAT Announces Management Board Change
11 March 2022
Russia business update and revised guidance
Russia business update and revised guidance
09 March 2022
BAT statement on Ukraine/Russia
BAT statement on Ukraine/Russia
17 February 2022
BAT appoints new Chief Medical Officer
BAT appoints new Chief Medical Officer
11 February 2022
Preliminary announcement - year ended 31 December 2021
Preliminary announcement - year ended 31 December 2021
11 February 2022
Share buyback programme
Share buyback programme
11 February 2022
British American Tobacco announces Board changes
British American Tobacco announces Board changes
20 January 2022
BAT recognised as Global Top Employer for fifth consecutive year
BAT recognised as Global Top Employer for fifth consecutive year
19 January 2022
BAT launches virtual R&D Visitor Experience, showcasing the world-class science behind next generation reduced-risk*† nicotine products
BAT launches virtual R&D Visitor Experience, showcasing the world-class science behind next generation reduced-risk*† nicotine products
07 January 2022
BAT creates biotech company KBio to accelerate development of existing plant-based technology
BAT creates biotech company KBio to accelerate development of existing plant-based technology
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the US, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced-risk claims will be made as to these products without FDA clearance.